[1] |
LIU Shuai, ZHANG Kai, ZHANG Xiaoqing, LUAN Wei.
An exploratory study on the perioperative treatment of locally advanced gastric cancer with combination of penpulimab, anlotinib and chemotherapy
[J]. China Oncology, 2024, 34(7): 659-668.
|
[2] |
LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua.
Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial
[J]. China Oncology, 2024, 34(2): 161-175.
|
[3] |
ZOU Ting, LIU Xiaowen.
Analysis of efficacy of hepatectomy and prognostic risk factors in patients with gastric cancer with synchronous liver metastasis
[J]. China Oncology, 2023, 33(6): 605-612.
|
[4] |
ZUO Xueliang, CHEN Zhiqiang, DONG Runyu, WANG Zhixiong, CAI Juan.
The value of combined detection of LDHA and PD-L1 in predicting the efficacy and prognosis of advanced gastric cancer patients treated with PD-1 inhibitor
[J]. China Oncology, 2023, 33(5): 460-468.
|
[5] |
CHEN Yingyao, CHU Xiangling, YU Xin, SU Chunxia.
Advances in models predicting efficacy of immune checkpoint inhibitors
[J]. China Oncology, 2023, 33(1): 61-70.
|
[6] |
YU Hang, LIU Wensheng, ZHANG Ning, LIU Haikuan, CHEN Luohai, YAO Wang, FAN Wenzhe, LI Jiaping, CHEN Jie, WANG Yu.
The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis
[J]. China Oncology, 2022, 32(9): 794-799.
|
[7] |
MEI Xiaoran, FENG Fang, WANG Hui, WEI Zhixiao.
Analysis of therapeutic response of iodine positive metastasis lymph nodes in differentiated thyroid cancer after 131I treatment
[J]. China Oncology, 2022, 32(11): 1091-1097.
|
[8] |
WEI Yu , ZHANG Tingwei , HE Yi , LI Jun , BI Jianbin , ZENG Yu , WAN Lijun , WU Gaoliang , WANG Huansheng , ZHANG Jun , ZHU Wei , QU Yuanyuan , ZHU Yao , YE Dingwei .
Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer
[J]. China Oncology, 2021, 31(7): 561-566.
|
[9] |
YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying .
Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(3): 203-211.
|
[10] |
SUN Jianda, XIONG Jun, ZHANG Hanxiong, CHEN Yibiao.
Prognostic values of hematological biomarkers in locoregionally advanced nasopharyngeal carcinoma
[J]. China Oncology, 2019, 29(7): 528-534.
|
[11] |
GAO Zhiqiang,WANG Weimin,CAI Yuqing,QIN Ruoyan,GU Aiqin,XIONG Liwen,HAN Baohui,JIANG Liyan,SHI Chunlei .
Clinical efficacy of osimertinib in the treatment of 62 patients with advanced lung adenocarcinoma
[J]. China Oncology, 2019, 29(10): 809-814.
|
[12] |
YANG Youqi, OU Xiaomin, ZHOU Xin, et al.
Clinical efficacy of GP, PF and TPF chemotherapy combined with intensity-modulated radiotherapy for nasopharyngeal carcinoma
[J]. China Oncology, 2018, 28(8): 602-608.
|
[13] |
ZHANG Yingqiang, ZHANG Xin, WANG Chen, et al.
The value of 18F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy
[J]. China Oncology, 2018, 28(7): 505-510.
|
[14] |
ZHANG Na, LIANG Jun, LIN Yansong.
The impact of thyroglobulin antibody on efficacy of 131I ablation in patients with papillary thyroid carcinoma
[J]. China Oncology, 2017, 27(6): 476-481.
|
[15] |
MAO Anrong, PAN Qi, ZHAO Yiming, et al.
The comparative analysis of clinical curative effect of laparoscopic hepatectomy and open resection for hepatic tumor
[J]. China Oncology, 2017, 27(4): 293-296.
|